For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 700,898 | 238,740.5 | 701,170 | 1,118,211 |
| Research and development | 400,000 | - | - | - |
| Total operating expenses | 1,100,898 | 238,740.5 | 701,170 | 1,118,211 |
| Loss from operations | -1,100,898 | -238,740.5* | -701,170 | -1,118,211 |
| Interest expense, related parties | 18,638 | 93,893* | 19,052 | 62,288 |
| Interest income | - | 3,440* | - | 24,383 |
| Forgiveness of unrelated vendor payables | - | -9,164,574* | - | 2,142,297 |
| Change in fair value of deferred underwriting fee - paid in common stock | - | 98,000* | 560,000 | -756,000 |
| Change in the fair value of warrant liabilities | 4,178 | -114,346.5* | -76,871 | 116,894 |
| Gain on exchange of common stock for warrants | - | 3,480,000* | -1,740,000 | - |
| Fair value of common stock to be issued for contingent liability | - | 1,840,000* | - | - |
| Total other expense, net | -22,816 | -7,402,680.5* | -1,122,181 | 1,231,498 |
| Net loss | -1,123,714 | -7,641,421 | -1,823,351 | 113,287 |
| Basic EPS | -0.03 | -0.365 | -0.07 | 0 |
| Diluted EPS | -0.03 | -0.365 | -0.07 | 0 |
| Basic Average Shares | 35,999,589 | 20,951,937 | 27,007,568 | 23,301,178 |
| Diluted Average Shares | 35,999,589 | 20,951,937 | 27,007,568 | 23,301,178 |
Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. (LIMN)